Morphine

  • Hard stuff
  • Cube juice
  • 7,8-didehydro-4,5-Epoxy-17-Methyl-Morphinan-3,6-diol
  • Dreamer
  • Duramorph
Formula
C17H19NO3
Structure
Description
Prisms. Odorless.
Uses
This is a drug of abuse.

Registry Numbers and Inventories.
CAS
57-27-2
EC (EINECS/ELINCS)
200-320-2
RTECS
QC7875000
RTECS class
Drug; Mutagen; Reproductive Effector; Human Data
Merck
12,6359
Beilstein/Gmelin
93703
Austrailia AICS
Listed
New Zealand
Listed

Properties.
Formula
C17H19NO3
Formula mass
285.34
Melting point, °C
254
Sublimation point, °C
190-200 (0.2 torr)
Density
1.31 g/cm3 (20 C)
Solubility in water
1.49x10+2 mg/L @ 20 C
pKa/pKb
8.21 (pKa)
Partition coefficient, pKow
0.76

Hazards and Protection.
Storage
Protect from light; store in airtight containers.
Handling
All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood.
Protection
Chemical splash goggles in compliance with OSHA regulations are advised; however, OSHA regulations also permit other type safety glasses. Whre chemical resistant gloves. To prevent repeated or prolonged skin contact, wear impervious clothing and boots.
Respirators
Use NIOSH/MSHA approved respirator appropriate for exposure of concern.
Small spills/leaks
Evacuate area and ventilate. Wear protective equipment. If required, use an inert absrobent. Sweep up and place in an appropriate container for disposal. Wash contaminated surfaces.
Stability
Morphine sulfate darkens on prolonged exposure to light. Morphine sulfate.
Incompatibilities
Strong oxidizing agents.

Fire.
Fire fighting
Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire.

Health.
Exposure effects
Abnormally low blood pressure and elevated body temperature or reduced body temperature may occur. lethargy and coma associated with pinpoint pupils occur frequently. Coma, seizures, myoclonic reactions, and spongiform encephalopathy and myelopathy have been reported in abusers of opioids.
   Ingestion
Delayed gastric emptying may result in cyclic coma.
   Inhalation
Respiratory depression leading to respiratory arrest, pulmonary edema, hypoxia, bronchospasm, acute asthma, bullous pulmonary damage, and pneumonitis have occurred and abuse of opioids.
   Skin
Rash has been reported during therapeutic use of opioid narcotics. Seborrhea may be seen following mptp overdoses. Scleroderma following heroin abuse has been reported and may be linked to talc mixed with heroin.
   Eyes
Pupils are usually pinpoint but may be dilated in the presence of severe acidosis, hypoxia, or respiratory depression.

First aid
 
   Ingestion
Seek medical attention. If individual is drowsy or unconscious, do not give anything by mouth; place individual on the left side with the head down. Contact a physician, medical facility, or poison control center for advice about whether to induce vomiting. If possible, do not leave individual unattended.
   Inhalation
Inhalation of opioids may result from drug abuse of persons crushing and snorting tablets. Clinical effects and treatment is based on the oral route of exposure.
   Skin
Flush skin with plenty of soap and water for at least 15 minutes while removing contaminated clothing and shoes.
   Eyes
If symptoms develop, immediately move individual away from exposure and into fresh air. Flush eyes gently with water for at least 15 minutes while holding eyelids apart; seek immediate medical attention.

Transport.